Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis

Clinical Infectious Diseases

Volumn 57, Issue 3, 2013, Pages 384-391

  Wolter, Daniel J ^a   Emerson, Julia C ^a   McNamara, Sharon ^a   Buccat, Anne M ^a   Qin, Xuan ^a   Cochrane, Elizabeth ^a   Houston, Laura S ^a   Rogers, Geraint B ^d   Marsh, Peter ^c   Prehar, Karandeep ^b   Pope, Christopher E ^a   Blackledge, Marcella ^a   Déziel, Eric ^e   Bruce, Kenneth D ^d   Ramsey, Bonnie W ^a   Gibson, Ronald L ^a   Burns, Jane L ^a   Hoffman, Lucas R ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e INRS INSTITUT ARMAND FRAPPIER   (Canada)

Author keywords

Children; Cystic fibrosis; Lung function; Small colony variant; Staphylococcus aureus

Indexed keywords

COTRIMOXAZOLE;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIUM COLONY; BACTERIUM CULTURE; BACTERIUM ISOLATION; CHILD; CULTURE TECHNIQUE; DISEASE ASSOCIATION; FEMALE; HUMAN; IN VIVO STUDY; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIXED INFECTION; NONHUMAN; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

CHILDREN; CYSTIC FIBROSIS; LUNG FUNCTION; SMALL-COLONY VARIANT; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL INTERACTIONS; PNEUMONIA, STAPHYLOCOCCAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; UNITED STATES;

EID: 84880382304     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit270     Document Type: Article

References (29)

1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918-51.
2. Cystic Fibrosis Foundation. 2011 Cystic Fibrosis Foundation patient registry report. Available at: http://www.cff.org/UploadedFiles/research/ ClinicalResearch/2011-Patient-Registry.pdf. Accessed 8 May 2013.
3. Di Sant'Agnese PEA, Andersen DH. Celiac syndrome; chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. Am J Dis Child 1946; 72:17-61.
4. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001; 32:277-87.
5. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34:91-100.
6. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009; 136:1554-60.
7. Sagel SD, Gibson RL, Emerson J, et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009; 154:183-8.
8. Gangell C, Gard S, Douglas T, et al. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis 2011; 53:425-32.
9. Pillarisetti N, Williamson E, Linnane B, et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011; 184:75-81.
10. Kahl BC. Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease. Int J Med Microbiol 2010; 300: 514-9.
11. Proctor RA, Von Eiff C, Kahl BC, et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006; 4:295-305.
12. Kahl BC, Duebbers A, Lubritz G, et al. Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study. J Clin Microbiol 2003; 41:4424-7.
13. Kahl B, Herrmann M, Everding AS, et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 1998; 177:1023-9.
14. Besier S, Smaczny C, Von Mallinckrodt C, et al. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Microbiol 2007; 45:168-72.
15. Schneider M, Mühlemann K, Droz S, Couzinet S, Casaulta C, Zimmerli S. Clinical characteristics associated with isolation of small-colony variants of Staphylococcus aureus and Pseudomonas aeruginosa from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 2008; 46:1832-4.
16. Yagci S, Hascelik G, Dogru D, Ozcelik U, Sener B. Prevalence and genetic diversity of Staphylococcus aureus small-colony variants in cystic fibrosis patients. Clin Microbiol Infect 2013 Jan; 19:77-84.
17. Gilligan PH, Gage PA, Welch DF, Muszynski MJ, Wait KR. Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis. J Clin Microbiol 1987; 25:1258-61.
18. Norström T, Lannergård J, Hughes D. Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:4438-46.
19. Hoffman LR, Déziel E, D'Argenio DA, et al. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 2006; 103:19890-5.
20. Biswas L, Biswas R, Schlag M, Bertram R, Götz F. Small-colony variant selection as a survival strategy for Staphylococcus aureus in the presence of Pseudomonas aeruginosa. Appl Environ Microbiol 2009; 75:6910-2.
21. Smyth A. Prophylactic antibiotics in cystic fibrosis: a conviction without evidence? Pediatr Pulmonol 2005; 40:471-6.
22. Cystic Fibrosis Trust. Consensus guidelines. Available at: http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/. Accessed 18 August 2012.
23. Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003; 2:29-34.
24. Cocchi P, Cariani L, Favari F, et al. Molecular epidemiology of meticillin-resistant Staphylococcus aureus in Italian cystic fibrosis patients: a national overview. J Cyst Fibros 2011; 10:407-11.
25. Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999; 28:321-8.
26. Sawicki GS, Rasouliyan L, Ren CL. The impact of MRSA on lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2009; 179:734-5; author reply 735.
27. Ren CL, Konstan MW, Yegin A, et al. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J Cyst Fibros 2012; 11:293-9.
28. Van Devanter DR. Antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Respiration 2007; 74:356.
29. Wagener JS, Rasouliyan L, Vandevanter DR, et al. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis [Epub ahead of print]. Pediatr Pulmonol 2012; Available at: http://www.ncbi.nlm.nih.gov/pubmed/22888106. Accessed 18 August 2012.